Elsevier

Auris Nasus Larynx

Volume 39, Issue 1, February 2012, Pages 1-8
Auris Nasus Larynx

Clinical practice guidelines for the diagnosis and management of acute otitis media (AOM) in children in Japan

https://doi.org/10.1016/j.anl.2011.09.008Get rights and content

Abstract

Objective

To (1) indicate methods of diagnosis and testing for acute otitis media (AOM) in children (under 15 years of age); and (2) recommend methods of treatment in accordance with the evidence based consensus reached by the subcommittee on clinical practice guidelines for the diagnosis and management of AOM in children (subcommittee on clinical practice guidelines), in light of the causative bacteria of AOM in Japan and their susceptibility to antimicrobial agents.

Methods

We investigated the most recently detected bacteria causing childhood AOM in Japan as well as their antimicrobial susceptibility, developed clinical questions concerning the diagnosis, testing methods, and treatment of AOM, searched the literature published during 2000–2004, and issued the 2006 guidelines. In the 2009 guidelines we performed the same investigation with the addition of literature that was published during 2005–2008 and that was not included in the 2006 guidelines.

Results

We categorized AOM as mild, moderate, or severe on the basis of otoscopic findings and clinical symptoms, and presented a recommended treatment for each degree of severity.

Conclusion

Accurate assessment of otoscopic findings, as well as other signs and symptoms, is important for judging the degree of severity and selecting a method of treatment.

Introduction

Acute otitis media (AOM) is a typical upper respiratory inflammation commonly affecting children and is mainly treated by otolaryngologists. Its exact frequency of occurrence in Japan is unknown, however. According to reports from Europe and the US, 62% of children aged less than one year and 83% of those up to the age of three have suffered from at least one bout of AOM [1]. Faden et al. [2] have reported that it affects 75% of children up to the age of one.

Some authors in Europe and the US do not recommend the use of antimicrobial agents for AOM. In the Netherlands, it has been proposed that antimicrobial agents are unnecessary in at least 90% of cases, and that patients should be observed for 3–4 days without antimicrobial agent administration [3], [4]. Rosenfeld et al. have also reported observation as a management option [5], [6], [7], and more recent studies have also found no significant difference in clinical outcome if antimicrobial agents are not given immediately but rather are prescribed if there is no improvement in symptoms after 48 or 72 h [8], [9]. A Cochrane review that examined randomized controlled trials of antimicrobial agent administration versus placebo also found that antimicrobial agents had little effect on childhood AOM [10]. In addition, a double-blind randomized controlled trial of amoxicillin (AMPC) and a placebo found no significant difference in therapeutic efficacy between the two [11], [12]. Dagan et al. [13], [14] and Toltzis et al. [15], in a review and case-control study, advised that antimicrobial agent use would be reduced because the use of a wide variety of antimicrobial agent increases the survival of resistant Streptococcus pneumonia (S. pneumonia) in the nasopharynx, which can cause additional infections in middle-ear (ME) fluid.

In Japan, regular nationwide surveys are performed of the causative bacteria for AOM, acute sinusitis, acute tonsillitis, and peritonsillar abscess. These surveys have reported that multidrug-resistant bacteria are now being detected more frequently [16], [17], which means that the recommendation to avoid administration of antimicrobial agents proposed in Europe and the US does not apply. In addition, the criteria and assessment levels used in conventional clinical assessment are not necessarily uniform even within Europe and the US [18]. Investigation and unified evaluation of the diagnosis and treatment of childhood AOM are therefore required, based on the actual situation in Japan. Based on this perspective, the Japan Otological Society (JOS), the Japan Society for Infectious Diseases in Otolaryngology (JSIDO), and the Japan Society for Pediatric Otorhinolaryngology (JSPO) produced 2006 clinical practice guidelines consistent with evidence-based medicine (EBM) [19] with the aim of supporting the diagnosis and treatment of childhood AOM [20], [21], [22], [23], which was revised and published in 2009 [24].

This paper introduces extracts of the important parts of our 2009 edition of clinical practice guideline for diagnosis and management of AOM in children.

Section snippets

Users

The main users of these guidelines will be otolaryngologists who perform otological procedures including the accurate evaluation of otoscopic findings and myringotomy.

Subjects

The subjects of these guidelines are AOM patients aged <15 years who were free from AOM or otitis media with effusion (OME) within one month prior to onset, who do not have a tympanostomy tube inserted, who have no craniofacial abnormality, and who do not suffer from immunodeficiency. Patients with the following conditions are excluded as subjects: AOM with complications including facial palsy and inner ear disorder, elevated pinna with acute mastoiditis, and AOM with Gradenigo's syndrome or

Gathering evidence

For the 2006 guidelines, PubMed and Japan Centra Revuo Medicina Web version 3 were used, and for the 2009 guidelines, PubMed, the Cochrane library, and Japan Centra Revuo Medicina Web version 4 were used.

Criteria for deciding recommendation grades

The method proposed by the Japan Stroke Society to indicate the level of evidence was used in the preparation of these guidelines, as shown below.

Pre-release review

Before these guidelines were released for general use, they were reviewed with reference to the Conference on Guideline Standardization (COGS) proposals concerning publication format [27] and the Appraisal of Guidelines for Research & Evaluation (AGREE) appraisal instrument for assessing content [28].

Before publication of the 2006 edition of the guidelines, opinions were solicited from the JOS, JSIDO, and JSPO, and pediatricians, and corrections were made where necessary. Otolaryngologists,

Recommendation

AOM is diagnosed when the following tympanic membrane findings are recognized, and thus, detailed inspection of the tympanic membrane is indispensable for its diagnosis (level of recommendation grade: B; hyperemia, protrusion, diminishment of the light reflex, thickening, bullar formation, cloudiness (turbidity), and perforation of the tympanic membrane, MEE, otorrhea, edema of middle-ear mucosa; references used to assess this recommendation level: Rosenfeld et al. [29] (Level IIb)).

Addendum

Treatment

The outcome of the treatment recommended by the present guidelines is defined by improvement of otoscopic findings such as hyperemia, protrusion, diminishment of the light reflex, thickening, bullar formation, cloudiness (turbidity), and perforation of the tympanic membrane, MEE, otorrhea, and edema of middle-ear mucosa at the time point of 3 weeks after onset. A score of 0 for the tympanic membrane and clinical manifestations except for age factor (under 24 months) is judged as cure of AOM.

A

Definition of ROM

The definition of ROM has yet to be standardized either in Japan or internationally, but in these guidelines it has been defined as three or more occurrences of AOM within the previous six months, or four or more within the previous 12 months, as generally used in comparatively recent studies [43], [44], [45].

Pathophysiology of and risk factors for ROM

The pathophysiology of ROM can be categorized into two types: recurrent simple AOM, and recurrent AOM occurring as an acute exacerbation in patients suffering from OME.

Proposed risk

References (59)

  • R.M. Rosenfeld et al.

    Natural history of untreated otitis media

  • R.M. Rosenfeld et al.

    Natural history of untreated otitis media

    Laryngoscope

    (2003)
  • D.M. Spiro et al.

    Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial

    JAMA

    (2006)
  • P. Little et al.

    Longer term outcomes from a randomized trial of prescribing strategies in otitis media

    Br J Gen Pract

    (2006)
  • P.P. Glasziou et al.

    Antibiotics for acute otitis media in children

    Cochrane Database Syst Rev

    (2004)
  • N. Le Saux et al.

    A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age

    CMAJ

    (2005)
  • D.P. McCormick et al.

    Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment

    Pediatrics

    (2005)
  • R. Dagan et al.

    Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment

    J Infect Dis

    (2001)
  • P. Toltzis et al.

    Impact of amoxicillin on pneumococcal colonization compared with other therapies for acute otitis media

    Pediatr Infect Dis J

    (2005)
  • K. Suzuki

    The status quo of drug-resistant bacteria in pediatric otolaryngological infectious diseases

    Pediatr Otorhinolaryngol Jpn

    (2000)
  • T. Nishimura et al.

    The third nationwide survey of clinical isolates from patients with otolaryngological field infections

    J Jpn Soc Infect Dis Otolaryngol

    (2004)
  • L.S. Chan et al.

    Evidence assessment of management of acute otitis media: II. Research gaps and priorities for future research

    Pediatrics

    (2001)
  • T. Nakayama

    Clinical practice guideline consistent with evidence-based medicine manual for development and application

    (2004)
  • Clinical Practice Guideline for Diagnosis and Management of Acute Otitis Media in Children. Otol Jpn 2006;16(Suppl. 1)...
  • Clinical practice guideline for diagnosis and management of acute otitis media in children. Pediatr Otorhinolaryngol...
  • Japan Council for Quality Healthcare Minds...
  • Clinical Practice Guideline for Diagnosis and Management of Acute Otitis Media in Children. Japan Otological Society,...
  • Clinical Practice Guideline for Diagnosis and Management of Acute Otitis Media in Children – 2009 edition. Japan...
  • Cited by (23)

    • The change of prevalence and recurrence of acute otitis media in Korea

      2020, International Journal of Pediatric Otorhinolaryngology
      Citation Excerpt :

      Worldwide, because the national economic burdens of AOM are also high, many countries including Korea have established guidelines for efficient treatment and management of AOM. And, there are slight differences in the details of these guidelines because the expression of pathogens and endemic strains varies in different countries [5,6]. There have been many recent changes in the treatment of AOM, including the introduction of a variety of vaccines to the population.

    • Post-myringotomy oto-liquorrhea in children - A case study and literature review

      2018, International Journal of Pediatric Otorhinolaryngology
    • Influence of pneumococcal conjugate vaccines on acute otitis media in Japan

      2018, Auris Nasus Larynx
      Citation Excerpt :

      Furthermore, there were some age groups that demonstrated an increase, although the reasons remain unknown. Changes in the rate of MyfA based on JGfCA 2006 and 2009 [6] were also investigated. To our knowledge, no other studies in Japan have utilized large datasets to analyze the detailed post-pfPCV trends by age group.

    • The effect of the leukotriene antagonist pranlukast on pediatric acute otitis media

      2016, International Journal of Pediatric Otorhinolaryngology
      Citation Excerpt :

      The guideline for treating children with AOM has been proposed by the Japan Otological Society [1]. Minor revisions to the guidelines were made in 2009 [2] and 2013, but treatment strategy is the same as for the 2006 guidelines. In this guideline, severity of AOM is classified as mild, moderate, and severe according to AOM score which is calculated depending on age, abnormal tympanic membrane findings, and clinical symptoms, then appropriate antibiotics are proposed.

    • Nationwide survey of the development of drug resistance in the pediatric field in 2007, 2010, and 2012: Drug sensitivity of haemophilus influenzae serotype b strain in Japan

      2015, Journal of Infection and Chemotherapy
      Citation Excerpt :

      Among these drugs, LVFX and TFLX showed the highest susceptibility of ≤0.063 μg/mL, which results were considered to reflect the fact that the quinolones are not affected by penicillin binding protein (PBP) mutations. The main factors that contribute to the maintenance of antimicrobial susceptibility are the proper use of antimicrobial agents in clinical practice, due to dissemination and implementation of various guidelines in the pediatric field [20,21], resulting in the prevention of emergence of drug-resistant strains [9]. In addition, it is considered that the new introduction of TFLX, as quinolone, into the treatment for pediatric infections, which previously depended on antimicrobial agents in the oral β-lactams, led to an increase in treatment options.

    • Nationwide survey of the development of drug resistance in the pediatric field in 2000-2001, 2004, 2007, 2010, and 2012: Evaluation of the changes in drug sensitivity of Haemophilus influenzae and patients' background factors

      2015, Journal of Infection and Chemotherapy
      Citation Excerpt :

      These figures show that the development of drug resistance has been well controlled in the West, due mainly to higher awareness of the importance of using antimicrobial agents properly [6]. In Japan, various guidelines for pediatric infections have been issued and updated every few years based on the latest knowledge about treatments for infections [15,16]. In fact, since there has been some success in controlling the development of drug resistance [6], these approaches appear to be achieving a positive result, but do not necessarily lead to a decrease in drug resistance.

    View all citing articles on Scopus
    *

    Corresponding author: Haruo Takahashi

    Department of Otolaryngology – Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki City, 852-8501, Japan. Tel.: +81 95 819 7349; fax: +81 95 819 7352.

    E-mail address: [email protected].

    View full text